New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2012
09:59 EDTWLP, SQNMWellpoint deems Sequenom pre-natal tests medically necessary for some patients
In a medical policy update with an effective date of Dec. 19, 2012, health insurer Wellpoint (WLP) stated that it views cell-free fetal DNA-based prenatal screening for fetal aneuploidies, including but not limited to Trisomy 13, Trisomy 18 and Trisomy 21, medically necessary for its members when certain criteria are met. Wellpoint stated there are currently several commercially available laboratory developed tests which analyze circulating cell-free DNA to identify increased representation of various chromosomes, including but not necessarily limited to the Sequenom's (SQNM) MaterniT21 Test and its MaterniT21 Plus Test, among others from Verinata Health and Aria Diagnostics. In early morning trading, shares of Sequenom rose 32c, or 6.84%, to $4.96, with the strength being attributed by some to Wellpoint's approval. Reference Link
News For SQNM;WLP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
16:40 EDTSQNMSequenom files $300M mixed securities shelf
Subscribe for More Information
August 25, 2015
17:32 EDTSQNMSequenom enters collaboration with UC San Diego Moores Cancer Center
Subscribe for More Information
August 24, 2015
08:29 EDTSQNMWilliam Blair to hold a field trip
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use